Abstract
The formation of senile plaques containing amyloid β peptides (Aβ peptides) as a major constituent plays a significant role in development of Alzheimers disease. The concentration of Aβ peptides in the brain is determined by a combination of their rate of synthesis and their rate of clearance. Considerable effort has been expended in producing inhibitors of the β and γ secretases involved in the synthesis of the Aβ peptides. More recently interest in the mechanism of clearance of the Aβ peptides has emerged, as promoting Aβ peptide clearance represents an alternative therapeutic approach. It now appears that cleavage of Aβ peptide by peptidases and proteases represents the major mechanism of clearance. This review describes those peptidases and proteases implicated in Aβ peptide clearance, the evidence that these enzymes function in vivo, and how they may represent new therapeutic targets.
Keywords: amyloid beta-peptide, ab, a betapeptides, b secretase, r secretase
Current Pharmaceutical Design
Title: Peptidases, Proteases and Amyloid β-Peptide Catabolism
Volume: 9 Issue: 6
Author(s): Louis B. Hersh
Affiliation:
Keywords: amyloid beta-peptide, ab, a betapeptides, b secretase, r secretase
Abstract: The formation of senile plaques containing amyloid β peptides (Aβ peptides) as a major constituent plays a significant role in development of Alzheimers disease. The concentration of Aβ peptides in the brain is determined by a combination of their rate of synthesis and their rate of clearance. Considerable effort has been expended in producing inhibitors of the β and γ secretases involved in the synthesis of the Aβ peptides. More recently interest in the mechanism of clearance of the Aβ peptides has emerged, as promoting Aβ peptide clearance represents an alternative therapeutic approach. It now appears that cleavage of Aβ peptide by peptidases and proteases represents the major mechanism of clearance. This review describes those peptidases and proteases implicated in Aβ peptide clearance, the evidence that these enzymes function in vivo, and how they may represent new therapeutic targets.
Export Options
About this article
Cite this article as:
Hersh B. Louis, Peptidases, Proteases and Amyloid β-Peptide Catabolism, Current Pharmaceutical Design 2003; 9 (6) . https://dx.doi.org/10.2174/1381612033391676
DOI https://dx.doi.org/10.2174/1381612033391676 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Beyond The Therapeutic Effect of rTMS in Alzheimer’s Disease: A Possible Neuroprotective Role of Hippocampal BDNF? : A Minireview
Mini-Reviews in Medicinal Chemistry Relapsing Remitting Multiple Sclerosis and its Relationship with the Immune System and Oxidative Stress
Current Immunology Reviews (Discontinued) Role of AGEs-RAGE System in Cardiovascular Disease
Current Pharmaceutical Design Ultra-micronized Palmitoylethanolamide Effects on Sleep-wake Rhythm and Neuropathic Pain Phenotypes in Patients with Carpal Tunnel Syndrome: An Open-label, Randomized Controlled Study
CNS & Neurological Disorders - Drug Targets The Intriguing Occurrence of Segmental Arterial Mediolysis: Case Report and Concise Literature Review
Cardiovascular & Hematological Disorders-Drug Targets Neopterin: From Forgotten Biomarker to Leading Actor in Cardiovascular Pathophysiology
Current Vascular Pharmacology New Insight Into A1 Adenosine Receptors in Diabetes Treatment
Current Pharmaceutical Design Antinociceptive Effects of VV-Hemorphin-5 Peptide Analogues Containing Amino phosphonate Moiety in Mouse Formalin Model of Pain
Protein & Peptide Letters ATP-Binding Cassette Efflux Transporters in Human Placenta
Current Pharmaceutical Biotechnology Brain Endothelial Cell-Cell Junctions: How to “Open” the Blood Brain Barrier
Current Neuropharmacology Monoamino Oxidase A: An Interesting Pharmacological Target for the Development of Multi-Target QSAR
Mini-Reviews in Medicinal Chemistry PET Studies of Brain Monoamine Transporters
Current Pharmaceutical Design Meet Our Editor
Infectious Disorders - Drug Targets Repetitive Transcranial Magnetic Stimulation to Treat Substance Use Disorders and Compulsive Behavior
CNS & Neurological Disorders - Drug Targets Meet Our Editorial Board Member:
Current Alzheimer Research Reduced Risk of Incident AD with Elective Statin Use in a Clinical Trial Cohort
Current Alzheimer Research Synthetic and Natural Lipase Inhibitors
Mini-Reviews in Medicinal Chemistry The Development of Medications for Alcohol-Use Disorders Targeting the GABAB Receptor System
Recent Patents on CNS Drug Discovery (Discontinued) Molecular and Clinical Aspects of the Target Therapy with the Calcimimetic Cinacalcet in the Treatment of Parathyroid Tumors
Current Cancer Drug Targets Alzheimers Disease and n-3 Polyunsaturated Fatty Acids: Beneficial Effects and Possible Molecular Pathways Involved
Current Signal Transduction Therapy